ACC: Safety and Efficacy of Two Drug-Eluting Stents Similar
Zotarolimus-eluting stent found as effective and safe as everolimus-eluting stent over two years
MONDAY, April 4 (HealthDay News) -- After two years, a novel zotarolimus-eluting stent appears to be as effective as an everolimus-eluting stent for patients in routine clinical practice, according to research published online April 3 in The Lancet to coincide with the American College of Cardiology's 60th Annual Scientific Session & Expo, held from April 2 to 5 in New Orleans.
In the RESOLUTE All Comers trial, Sigmund S. Silber, M.D., of Heart Centre at the Isar in Munich, Germany, and colleagues randomized patients with at least one coronary lesion 2.25 to 4.0 mm in diameter, with greater than 50 percent stenosis, at 17 centers in Europe and Israel to a Resolute zotarolimus-eluting stent or a Xience V everolimus-eluting stent. They assessed safety and efficacy at two years.
The investigators found that the patient related outcome -- all death, all myocardial infarction, all revascularization -- did not differ significantly between the groups, and neither did the stent-related outcome, even though rates of the stent-related outcome were substantially lower than those for the patient-related outcome.
"The safety and efficacy of these two drug-eluting stents are clinically equivalent, even after two years in a mostly complex population," the authors write.
The study was funded by Medtronic, the manufacturer of the zotarolimus-eluting stent used in the study (Resolute), with two authors disclosing financial relationships with Medtronic and Abbott, the manufacturer of the everolimus-eluting stent used in the study (Xience V), as well as other medical device companies.